World’s first lignocellulose biorefinery is on its way


Leuna – Peak oil prices and depleted fossil resources have dragged biomass into the limelight in the chemical industry. In Germany, pioneering work to use wood waste to produce bioplastics, platform chemicals or energy in a biorefinery has begun. In mid-June, a consortium of 15 research groups – including those from Bayer Technology GmbH, Evonik Degussa, Wacker Chemie AG, and the SMEs Dynea Erkner, Tecnaro and InfraLeuna GmbH – received an initial a8.5m tranche of funding to set up the world’s first lignocellulose pilot plant at the traditional chemistry production site in Leuna. The facility they are planning to build will be able to break down cellulose, hemicellulose and lignin into glucose, xylose and phenols. It is part of a a50m fund set up for the Chemical Bio­tech Process Center (CBP), a complete bio­refinery designed to scale-up biotechnological conversions from the lab to the pilot scale, a prerequisite for companies to commercialise such technologies.
To be managed by the Fraunhofer Ge­sellschaft and Linde-KCA Dresden, the pilot biorefinery will feature seven plants where biotech processes can be upscaled. In contrast to plant-made starches, conversion of wood waste to chemical products is promising because wood is significantly cheaper than raw oil (EUR70/t vs. EUR480/t).

Breaking the bonds = Big money

The cellulose and hemicellulose building blocks of wood can be converted to glucose and xylose, whereas lignin can be degraded to phenol, a precursor for many chemical products.
The profitability of the biorefinery will depend primarily on the exploitation of lignin, which is difficult to crack economically. In the consortium, Wacker Chemie AG has already begun to develop pro­cesses for its enzymatic breakdown, while Dynea Erkner is very interested in the production of bioplastics from phenol building blocks. Evonik Degussa GmbH and Bayer Technology Services GmbH are also looking at how to use wood waste as an alternative feed for the sugar supply.

Germany, FranceGermany


Martinsried/Paris - Sanofi has done some Christmas shopping in Munich and has licensed Scil Technology’s programme for the regenerative treatment of osteoarthritis and cartilage disorders. Under the agreement, Scil could reap up...



Monheim - It's nearly Christmas, and Bayer Crop Science gives out some presents. As the company announced, a $750 million settlement with U.S. rice farmers is now binding and can move forward. In summer the German firm had agreed...



Bonn – Germany’s federal government is prolonging one of its most successful measures to date for stimulating the establishment of high-tech companies – the High-Tech-Gründerfonds (HTGF). The HTGF was launched in 2005 with €272m...



Leverkusen – One short statement from the European Medicines Agency (EMA) means one giant step for German biotech company Biofrontera. The agency issued a favourable opinion on the firm’s marketing approval application for its...



While the European sovereign debt crisis keeps capital markets in a choke-hold, with potential negative effects on the financing situation in many industries – including biotech – there was encouraging news for drug-developing...



Heidelberg – There is still life in the European life science finance. EMBL Ventures has closed a €40m fund. The early stage investor and the venture capital arm of the European Molecular Biology Laboratory(EMBL) announced the...



Düsseldorf – BIO-Europe 2011 in Düsseldorf has again broken all previous records in terms of participants and company numbers. More than 3,000 representatives from 1,800 companies registered for Europe‘s largest partnering event....



Brussels/San Francisco – As the biggest biotech partnering event on the continent, BioEurope, draws to a close, the venture capital community sent ambivalent messages for life sciences. Dow Jones VentureSource, an analyst,...

Displaying results 11 to 20 out of 454

< Previous 11-20 Next >

© 2007-2015 BIOCOM


All videos

Product of the week



All Events

Stock list

All quotes


  • BAVARIAN NORDIC (D)41.03 EUR20.85%
  • TIGENIX (B)1.02 EUR17.24%


  • THROMBOGENICS (B)2.90 EUR-6.15%
  • EVOCUTIS (UK)0.19 GBP-5.00%


  • KARO BIO (S)38.10 SEK2281.2%
  • TRANSGENE (F)5.08 EUR80.8%
  • TIGENIX (B)1.02 EUR30.8%


  • THROMBOGENICS (B)2.90 EUR-42.9%
  • BIONOR PHARMA (N)1.28 NOK-37.6%
  • WILEX (D)2.05 EUR-36.5%


  • KARO BIO (S)38.10 SEK4546.3%
  • ADOCIA (F)86.70 EUR432.2%
  • VERONA PHARMA (UK)4.92 GBP339.3%


  • CHRONTECH PHARMA (S)0.01 SEK-85.7%
  • BIOTEST (D)19.92 EUR-76.0%
  • NEOVACS (F)0.96 EUR-72.7%

No liability assumed, Date: 29.08.2015

Current issue

All issues